6.
Ranjbarvaziri S, Kooiker K, Ellenberger M, Fajardo G, Zhao M, Vander Roest A
. Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation. 2021; 144(21):1714-1731.
PMC: 8608736.
DOI: 10.1161/CIRCULATIONAHA.121.053575.
View
7.
Tsuchida M, Miura T, Mizutani K, Aibara K
. Fluorescent substances in mouse and human sera as a parameter of in vivo lipid peroxidation. Biochim Biophys Acta. 1985; 834(2):196-204.
View
8.
Korovila I, Hugo M, Castro J, Weber D, Hohn A, Grune T
. Proteostasis, oxidative stress and aging. Redox Biol. 2017; 13:550-567.
PMC: 5536880.
DOI: 10.1016/j.redox.2017.07.008.
View
9.
Fang L, Ellims A, Beale A, Taylor A, Murphy A, Dart A
. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res. 2017; 9(11):5063-5073.
PMC: 5714791.
View
10.
Lillo R, Graziani F, Franceschi F, Iannaccone G, Massetti M, Olivotto I
. Inflammation across the spectrum of hypertrophic cardiac phenotypes. Heart Fail Rev. 2023; 28(5):1065-1075.
PMC: 10403403.
DOI: 10.1007/s10741-023-10307-4.
View
11.
Dimitrow P, Undas A, Wolkow P, Tracz W, Dubiel J
. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacol Rep. 2009; 61(3):491-5.
DOI: 10.1016/s1734-1140(09)70091-x.
View
12.
Senoner T, Dichtl W
. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target?. Nutrients. 2019; 11(9).
PMC: 6769522.
DOI: 10.3390/nu11092090.
View
13.
Maung M, Carlson A, Olea-Flores M, Elkhadragy L, Schachtschneider K, Navarro-Tito N
. The molecular and cellular basis of copper dysregulation and its relationship with human pathologies. FASEB J. 2021; 35(9):e21810.
DOI: 10.1096/fj.202100273RR.
View
14.
Elliott P, Anastasakis A, Borger M, Borggrefe M, Cecchi F, Charron P
. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39):2733-79.
DOI: 10.1093/eurheartj/ehu284.
View
15.
Jozwiak J, Studzinski K, Tomasik T, Windak A, Mastej M, Catapano A
. The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atheroscler Suppl. 2021; 42:e15-e24.
DOI: 10.1016/j.atherosclerosissup.2021.01.004.
View
16.
Arbelo E, Protonotarios A, Gimeno J, Arbustini E, Barriales-Villa R, Basso C
. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44(37):3503-3626.
DOI: 10.1093/eurheartj/ehad194.
View
17.
Volchegorskii I, Shaposhnik I, Alekseev E, Kharchenkova N
. [Indices of the lipid peroxidation--antioxidant defense system as markers of chronic cardiac failure in cardiomyopathies]. Klin Med (Mosk). 2003; 81(8):26-8.
View
18.
Nakamura K, Kusano K, Matsubara H, Nakamura Y, Miura A, Nishii N
. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail. 2005; 11(2):117-23.
DOI: 10.1016/j.cardfail.2004.05.005.
View
19.
Takimoto E, Kass D
. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2006; 49(2):241-8.
DOI: 10.1161/01.HYP.0000254415.31362.a7.
View
20.
Kakimoto Y, Okada C, Kawabe N, Sasaki A, Tsukamoto H, Nagao R
. Myocardial lipofuscin accumulation in ageing and sudden cardiac death. Sci Rep. 2019; 9(1):3304.
PMC: 6397159.
DOI: 10.1038/s41598-019-40250-0.
View